Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 9:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 115 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacology, Clinical Clear all
Completed Phase 1 Interventional

Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs

NCT00020124
View directory record Official record
Conditions
Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
Interventions
doxorubicin hydrochloride
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 11, 2026, 9:08 PM EDT
Not yet recruiting Not applicable Interventional

Sleep Harmonization Via Bundled Team-Based Interventions in the ICU

NCT07840560
View directory record Official record
Conditions
Sleep Deprivation, Critical Illness, Sleep-Wake Disorders, Bundle Care, Implementation Science, Delirium
Interventions
Nighttime noise & light reduction, Clustering patient-care interactions, Non-pharmacologic sleep aids, Daytime light exposure, Encourage out-of-bed activity, Medication management to support nighttime sleep
Behavioral · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
62,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
La Jolla, California • San Francisco, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Not applicable Interventional

Artificial Intelligence in Depression - Medication Enhancement

NCT04655924
View directory record Official record
Conditions
Depression
Interventions
Clinical Decision Support System
Device
Lead sponsor
Aifred Health
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
West Haven, Connecticut • Miami, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid

NCT01009216
View directory record Official record
Conditions
Healthy
Interventions
ABT-384
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2010 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Phase 2 Interventional Results available

Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent

NCT01681095
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Ischemia, Coronary Disease, Heart Diseases, Valvular Heart Disease
Interventions
Custodiol HTK, Cold Blood Cardioplegia
Drug
Lead sponsor
Marc Sakwa, MD
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

NCT03648827
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
2 Years to 7 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 11, 2026, 9:08 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Understanding Oral Nicotine Pouch Use in Healthy Volunteers

NCT07829939
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
0 mg oral nicotine pouches, 3 mg oral nicotine pouches, 6 mg oral nicotine pouches, cigarette or e-cigarette
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Early Phase 1 Interventional

Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders

NCT01519557
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
DAR-100A, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Phase 3 Interventional

Paclitaxel in Treating Older Patients With Solid Tumors

NCT00003092
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
paclitaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
55 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
32
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 11, 2026, 9:08 PM EDT
Terminated Phase 1 Interventional

Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies

NCT04865159
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Tipifarnib
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Canton, Ohio • Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 11, 2026, 9:08 PM EDT
Completed No phase listed Observational

Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)

NCT02252159
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Not listed
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
264
States / cities
Green Valley, Arizona • Safford, Arizona • Scottsdale, Arizona + 261 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

NCT01707407
View directory record Official record
Conditions
Pharmacology, Clinical, Healthy
Interventions
Pomalidomide, Ketoconazole, Fluvoxamine, Carbamazepine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State

NCT00490542
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression, Depression
Interventions
ziprasidone (Geodon), placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Cambridge, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.

NCT02394093
View directory record Official record
Conditions
Pharmacology, Clinical
Interventions
Aspirin (Acetylsalicylic acid, BAYe4465)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Phase 2 Interventional Results available

Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness

NCT01036321
View directory record Official record
Conditions
Prostate Cancer
Interventions
Purified isoflavones, Methyl cellulose blend
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
30 Years to 80 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
3
States / cities
Jacksonville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Phase 4 Interventional

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

NCT05657860
View directory record Official record
Conditions
Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
Interventions
Guanfacine Extended Release, Placebo
Drug · Other
Lead sponsor
Maimonides Medical Center
Other
Eligibility
6 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions

NCT03424135
View directory record Official record
Conditions
Clinical Pharmacology
Interventions
Naproxen sodium and diphenhydramine hydrochloride soft capsules, Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment

NCT02852239
View directory record Official record
Conditions
Renal Impairment
Interventions
dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
DeBary, Florida • Berlin, New Jersey • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Phase 2 Interventional Results available

Comparison of A Single Dose Combination of Methadone and Morphine With Morphine Alone for Treating Post-operative Pain

NCT00142519
View directory record Official record
Conditions
Pain
Interventions
Methadone, methadone and morphine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Phase 4 Interventional

Effectiveness Study of Single Photon Emission Computed Tomography (SPECT) Versus Positron Emission Tomography (PET) Myocardial Perfusion Imaging

NCT00976053
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Myocardial perfusion imaging
Procedure
Lead sponsor
Aspire Foundation
Other
Eligibility
30 Years to 90 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects

NCT03517930
View directory record Official record
Conditions
Clinical Pharmacology
Interventions
Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG), Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Phase 2 Interventional Results available

Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM

NCT00004146
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
radiation therapy, carboxyamidotriazole, pharmacological study
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
8
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 11, 2026, 9:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects

NCT00968422
View directory record Official record
Conditions
Healthy
Interventions
ABT-384, Matching placebo to ABT-384
Drug
Lead sponsor
Abbott
Industry
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2010 · Synced Oct 11, 2026, 9:08 PM EDT
Terminated No phase listed Observational

An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®

NCT02455024
View directory record Official record
Conditions
Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL
Interventions
Not listed
Lead sponsor
Ariad Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Hackensack, New Jersey • Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 11, 2026, 9:08 PM EDT